Nature Communications (Jul 2023)
Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
- Richard Hill,
- Patricia A. Madureira,
- Bibiana Ferreira,
- Inês Baptista,
- Susana Machado,
- Laura Colaҫo,
- Marta dos Santos,
- Ningshu Liu,
- Ana Dopazo,
- Selma Ugurel,
- Angyal Adrienn,
- Endre Kiss-Toth,
- Murat Isbilen,
- Ali O. Gure,
- Wolfgang Link
Affiliations
- Richard Hill
- Department of Biomedical Sciences and Medicine (DCBM), University of Algarve
- Patricia A. Madureira
- Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas
- Bibiana Ferreira
- Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas
- Inês Baptista
- Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas
- Susana Machado
- Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas
- Laura Colaҫo
- Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas
- Marta dos Santos
- Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas
- Ningshu Liu
- Bayer AG, Drug Discovery Oncology Research
- Ana Dopazo
- Genomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC)
- Selma Ugurel
- Department of Dermatology, University Hospital Essen
- Angyal Adrienn
- Department of Cardiovascular Science, University of Sheffield
- Endre Kiss-Toth
- Department of Cardiovascular Science, University of Sheffield
- Murat Isbilen
- Department of Molecular Biology and Genetics, Bilkent University
- Ali O. Gure
- Department of Molecular Biology and Genetics, Bilkent University
- Wolfgang Link
- Department of Biomedical Sciences and Medicine (DCBM), University of Algarve
- DOI
- https://doi.org/10.1038/s41467-023-40050-1
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 1
Abstract
No abstracts available.
